Patents Examined by James Schultz
-
Patent number: 7229757Abstract: Icosahedral phage and collections thereof that display various compounds are provided. In some instances, the icosahedral phage include nucleic acid tags that serve to record a characteristic of the compound or compounds that are attached to the phage. A number of different methods for using the icosahedral phage to screen a library of compounds for a desired biological activity are also provided, especially assays for compounds that are substrates for receptor-mediated transport processes such as endocytosis and transcytosis.Type: GrantFiled: March 21, 2002Date of Patent: June 12, 2007Assignee: Xenoport, Inc.Inventors: Ronald W. Barrett, William J. Dower, Mark Gallop, Thomas F. Woiwode, Steven E. Cwirla
-
Patent number: 7223849Abstract: The invention relates to oligonucleotides from the untranslated regions of housekeeping genes, and methods and compositions for modulating cell growth using same. Specifically it relates to the use of the untranslated regions (UTR) from housekeeping genes specifically the R1 and R2 components of ribonucleotide reductase UTR, for inhibiting tumor cell growth.Type: GrantFiled: June 30, 1997Date of Patent: May 29, 2007Assignee: Genesense Technologies Inc.Inventors: Jim A. Wright, Aiping H. Young
-
Patent number: 7223857Abstract: The present invention provides a chain-shortened polynucleotide wherein the proportion of a 2?-5? phosphodiester bond is up to 3% based on the whole phosphodiester bonds or a salt thereof and a pharmaceutical composition containing the same, and a method for producing the same.Type: GrantFiled: June 22, 2004Date of Patent: May 29, 2007Assignee: Nippon Shinyaku Co., Ltd.Inventors: Shinji Matsuyama, Kouichi Ishiyama, Junzo Seki, Tadaaki Ohgi
-
Patent number: 7214790Abstract: The present invention encompasses novel mammalian cell cycle checkpoint genes/DNA repair genes, cDNA or genomic DNA, isolated nucleic acids corresponding thereto, expression vectors comprising said nucleic acids, host cells transformed with said expression vectors, pharmaceutical compositions and the formulation of such compositions comprising said nucleic acids or proteins expressed therefrom, methods for treating a cell using such nucleic acids, proteins or pharmaceutical compositions, and the use of such nucleic acids or proteins in formulating a pharmaceutical preparation.Type: GrantFiled: August 27, 2002Date of Patent: May 8, 2007Assignees: The Scripps Research Institute, Janssen Pharmaceutica N.V.Inventors: Paul R. Russell, Jorge E. Vialard, Michael N. Boddy, Paul A. Shanahan, Antonia Lopez-Girona, Cecile-Marie D. D. Denis, Clare H. McGowan
-
Patent number: 7211661Abstract: A group I intron-derived ribozyme which binds RNA in trans, excises an internal segment from within the RNA, and splices the remaining 5? and 3? ends of the RNA back together (the trans-excision-splicing reaction) is disclosed. The excised segment can be as long as 28 nucleotides, or more, and as little as one nucleotide. The ribozymes of the invention are easily modified to alter their sequence specificity. Such ribozymes represent a new and potentially powerful class of generally adaptable genetic therapeutics.Type: GrantFiled: December 9, 2003Date of Patent: May 1, 2007Assignee: University of Kentucky Research FoundationInventors: Stephen M. Testa, Michael A. Bell
-
Patent number: 7208268Abstract: Disclosed herein are methods for identifying, isolating and comparing proteins and other biomolecules differing between two complex biological samples using affinity chromatography and phage display techniques.Type: GrantFiled: December 13, 2001Date of Patent: April 24, 2007Inventor: Paul Stroobant
-
Patent number: 7205157Abstract: Rare cells are separated from a sample fluid by a positive selection or negative selection antibody by centrifuging in a tube containing a harvesting float. The harvesting float has an axial passage and a density to settle in the sample fluid and expand the layer of the target component. The antibody is preferably coupled to a particulate carrier, such as a microbead, to attach either the target component or a contaminating component to the particulate carrier. In the positive separation, the particulate carrier is recovered in the axial passage of the float.Type: GrantFiled: January 8, 2001Date of Patent: April 17, 2007Assignee: Becton, Dickinson and CompanyInventors: Stewart Russell Jurgensen, Sheila Ann Lloyd
-
Patent number: 7205120Abstract: The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a ?-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.Type: GrantFiled: July 19, 2001Date of Patent: April 17, 2007Assignee: Pharmacia & Upjohn CompanyInventors: Riqiang Yan, Alfredo G. Tomasselli, Mark E. Gurney, Thomas L. Emmons, Michael Jerome Bienkowski, Robert L. Heinrikson
-
Patent number: 7199109Abstract: This patent application discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene comprising: Sense strand: 5? UGAAGGAUCUUAUUUCUUCdTdT 3? (SEQ ID NO: 1) Anti sense strand: 3? dTdTACUUCCUAGAAUAAAGAAG 5? (SEQ ID NO: 2) Sense strand: 5? UGAAGGAUCUUAUUUCUUCGGdTdT 3? (SEQ ID NO: 3) Anti sense strand: 3? dTdTACUUCCUAGAAUAAAGAAGCC 5? (SEQ ID NO: 4) Sense strand: 5? GGAUCUUAUUUCUUCGGAGACdTdT 3? (SEQ ID NO: 5) Anti sense strand: 3? dTdTCCUAGAAUAAAGAAGCCUCUG 5? (SEQ ID NO: 6) said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans.Type: GrantFiled: June 2, 2006Date of Patent: April 3, 2007Assignee: Cal Poly Pomona FoundationInventors: Bijay K. Pal, Lynn M. Tran
-
Patent number: 7196067Abstract: Compositions and a method are provided for the treatment of prostate and other endocrine tumors in mammals, including humans, by administration of an antisense oligodeoxynucleotide (ODN) which is complementary to a portion of the gene encoding IGFBP-2. Using the Shionogi tumor model in vitro and in vivo, the administration of such an ODN was shown to reduce proliferation of tumor cells, and also to delay the progression to androgen independence. Thus, treatment of prostate and other hormone-regulated cancer in mammals, including humans, and delay of the progression of prostate tumors to androgen independence is accomplished by administering to the mammal a therapeutically effective amount of an antisense oligodeoxynucleotide which is complementary to a portion of the nucleic acid sequence encoding IGFBP-2 and which reduces the amount of IGFBP-2 in the treated cells.Type: GrantFiled: September 13, 2001Date of Patent: March 27, 2007Assignee: The University of British ColumbiaInventors: Martin Gleave, Paul S. Rennie, Kiyama Satoshi, Colleen Nelson
-
Patent number: 7192708Abstract: A method of detecting the presence of an ion includes contacting a nucleic acid enzyme with a sample suspected of containing the ion, where the enzyme contains a ribonucleotide and is dependent on the ion to produce a product from a substrate, and measuring an amount of the product produced. The ion is Pb2+, and is in the presence of other ions.Type: GrantFiled: November 6, 2003Date of Patent: March 20, 2007Assignee: The Board of Trustees of the University of IllinoisInventors: Yi Lu, Jing Li
-
Patent number: 7192932Abstract: Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.Type: GrantFiled: October 28, 1999Date of Patent: March 20, 2007Assignee: Lauras ASInventors: Kjetil Taskén, Einar M. Aandahl, Pål Aukrust, Bjørn S. Skålhegg, Fredrik Müller, Stig Frøland, Vidar Hansson
-
Patent number: 7189832Abstract: The present invention provides a novel essential regulatory subunit of the I?B kinase (IKK) complex, IKK-?. The isolated IKK-? subunit of the invention has substantially the same amino acid sequence as SEQ ID NO: 2 shown in FIG. 2.Type: GrantFiled: August 20, 1999Date of Patent: March 13, 2007Assignee: The Regents of the University of CaliforniaInventors: Michael Karin, David M. Rothwarf, Ebrahim Zandi
-
Patent number: 7176304Abstract: The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity.Type: GrantFiled: May 11, 2004Date of Patent: February 13, 2007Inventors: James McSwiggen, Leonid Beigelman, Pamela Pavco
-
Patent number: 7176302Abstract: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.Type: GrantFiled: June 16, 2003Date of Patent: February 13, 2007Assignee: Board of Regents, the University of Texas SystemInventors: Gabriel Lopez-Berestein, Ana Maria Tari
-
Patent number: 7176295Abstract: A method is described for generating blended nucleic acid ligands containing non-nucleic acid functional units. Specifically, a SELEX identified RNA ligand to the integrin gpIIbIIIa is conjugated to the peptide Gly-Arg-Gly-Asp-Thr-Pro (SEQ ID NO:1). This blended RNA ligand inhibits the biological activity of gpIIbIIIa with high specificity. Also described is a single-stranded DNA ligand to elastase coupled to N-methoxysuccinyl-Ala-Ala-Pro-Val-chloromethyl ketone (SEQ ID NO:2). This elastase blended nucleic acid ligand inhibits the biological activity of elastase.Type: GrantFiled: October 2, 2002Date of Patent: February 13, 2007Assignee: Gilead Sciences, Inc.Inventors: Gregory Biesecker, Sumeda Jayasena, Larry Gold, Drew Smith, Gary P. Kirschenheuter
-
Patent number: 7173122Abstract: The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene.Type: GrantFiled: December 12, 2000Date of Patent: February 6, 2007Inventor: Rajinder Beri
-
Patent number: 7160868Abstract: The present invention relates to the identification of a novel role of Nr-CAM in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of Nr-CAM in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for Nr-CAM. Further, the present invention relates, in part, to the Applicants' surprising discovery that the inhibition of Nr-CAM gene expression or the inhibition of Nr-CAM activity in transformed cells reverses the transformed phenotype.Type: GrantFiled: April 27, 1999Date of Patent: January 9, 2007Inventors: Gerald P. Murphy, Alton L. Boynton, Anil Sehgal
-
Patent number: 7150970Abstract: The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells).Type: GrantFiled: August 1, 2005Date of Patent: December 19, 2006Assignee: University of Iowa Research FoundationInventors: Douglas K. Trask, Jonathan Bock
-
Patent number: 7138511Abstract: In a preferred aspect of the invention, the upstream sequences of the TIGR protein encoding sequence can be used to diagnose a sensivity to steroids and a risk for glaucoma or ocular hypertensive disorders. Methods, kits, and nucleic acids containing polymorphisms, base substitutions, or base additions located within the upstream region and within protein-encoding regions of the TIGR gene are also provided. The upstream sequences disclosed, including the TIGR promoter regions and those regions possessing functional characterisitics associated with or possesssed by the TIGR gene 5?regulatory region, can also be used to generate cells, vectors, and nucleic acids useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions, and methods.Type: GrantFiled: January 11, 1999Date of Patent: November 21, 2006Assignee: The Regents of the University of CaliforniaInventors: Thai D. Nguyen, Jon R. Polansky, Pu Chen, Hua Chen